ST. DOMINIC’S PHYSICIANS WORK TO REDUCE CHRONIC PAD

By admin
November 12, 2012

JACKSON, Miss – An estimated 18 million Americans suffer from Peripheral Artery Disease (PAD), a narrowing of the arteries most commonly in the pelvis and legs, which causes oxygen loss to limbs. This deprivation can cause painful cramping, sores and eventually leads to amputation if left untreated.

St. Dominic’s has led the way in the treatment of PAD by becoming the only site in Mississippi that is FDA approved for continued use of Avinger’s Ocelot device in the Connect II Trial. This innovative device is a minimally invasive option for the treatment of severe PAD. There are only 12 sites in the country approved to continue this study. St. Dominic’s has treated more patients in this study than anywhere else, worldwide.

Physicians at St. Dominic’s who have gained extensive expertise in the use of the Avinger devices, recently hosted a CTO (chronic total occlusion) course for several physicians from east Mississippi, Louisiana, and Tennessee. This course focused on treating severe PAD cases with FDA approved Avinger devices.

“We constantly strive for a better way to treat patients with PAD,” said Huey McDaniel, M.D., Cardiovascular Surgeon and Lead Investigator of the Connect II Trial at St. Dominic’s. “This sometimes involves using experimental devices with tremendous potential.”

“We have been using the Avinger Wildcat and Kittycat to cross completely blocked arteries since 2010 and have amassed quite a bit of experience with them,” said William Crowder, M.D., Medical Director of St. Dominic’s Cath Lab. “We wanted to show the versatility of these devices so the visiting physicians could gain insight into using them to treat complex PAD and CTO cases.”

The Ocelot device and continuation of the Connect II trial have been temporarily approved by the FDA due to the device’s success, but the raw data is still in the review process for final approval.

For additional information contact Margaret Mays, Marketing Specialist at 601-200-6912.

Comments are closed.